Page 188«..1020..187188189190..200210..»

The real power ofimproved genetics – Farming Life

Posted: October 4, 2022 at 2:00 am

So maybe its time to take a peek at what scientists around the world are striving to achieve, where developments in the science of genetic development is concerned.

Lets start with the world of plants. There are three main crops responsible for delivering all of the plant-based energy and protein required in the world today. These consumed directly by mankind or fed to livestock in order to produce animal protein.

The crops in question are: wheat, maize (corn) and soya bean. Given Northern Irelands temperate climate, wheat is the one which farmers and consumers will be most familiar with.

So here comes the shocking fact: A first-of-its-kind analysis of the untapped genetic potential of wheat shows global yields are only half of what they could be!

The team of international experts, led from the UKs Rothamsted Research, says this genetic yield gap could be closed by developing wheat varieties tailored to each region.

In other words, by utilising the vast genetic variation available in global and historical wheat gene banks with modern techniques such as speed breeding and gene editing.

Dr Mikhail Semenov and Dr Nimai Senapati, who co-led this study, define a crops genetic yield potential as the highest yield achievable by an idealised variety.

A plant with an optimal genome allows it to capture water, sunlight and nutrients more efficiently than any other.

Dr Semenov said: Current wheat cultivars are, on average, only at the half-way point with respect to the yields they could produce given the mismatches between their genetics and local wheat growing conditions.

Global wheat production could be doubled by the genetic improvement of local wheat cultivars - without increasing global wheat area.

Using existing data on the contribution of different genes to individual plant traits such as size, shape, metabolism and growth, the researchers ranmillions of computer simulations to design perfect wheat plantsthat were tailored to their local environments.

When compared to the performance of locally adapted cultivars, in all cases they found current wheat varieties were underperforming for grain yield, with an obvious genetic yield gap between reality and possibility.

According to Dr Senapati, closing the genetic yield gap would go a long way to feeding the growing world population and would reduce pressure to convert wild habitats to farmland.

Using a state-of-the-art wheat model, called Sirius, the team first calculated the potential yield from a total of 28 commonly used wheat varieties grown at a number of sites around the world, assuming the best possible cultivation conditions for each one.

This gave harvests of less than four tons in Australia and Kazakhstan - compared with 14 tons of wheat produced per hectare in New Zealand.

Next, they designed idealized local varieties within their model, which optimised several plant traits that contribute to yield and whose underlying genetics will allow them to be improved by plant breeders.

Simulations were based on extensive data on the natural genetic variation underpinning the traits.

These included tolerance and response to drought and heat stresses, the size and orientation of the light-capturing upper leaves, and the timing of key life cycle events.

The results showed that by optimizing these key traits, genetic yield gaps could be anywhere from 30-70% across different countries, with a global average genetic yield gap of 51%. Therefore, global wheat production could be doubled by exploiting this existing genetic yield gap towards achieving global food security in a sustainable way.

Not unsurprisingly, the countries with the lowest current yields could gain the most from closing their genetic yield gaps, said Dr Senapati.

That said, even improvements in those countries with a medium genetic yield gap of 40 to 50%, but with a large proportion of the global wheat harvest, would have a substantial effect on global wheat production due to the larger wheat cultivation areas involved.

Meanwhile, here in Ireland, sheep production has been a key focus of genetic research for many years.

In fact, the myriad sources of data now available to Sheep Ireland is allowing the organisation to achieve the role it was created to fulfil on its establishment back in 2009.

This was the core message delivered by Sheep Irelands manager, Kevin McDermott, courtesy of his presentation to the recent EasyCare open evening. The event was held on the Co Antrim farm of Campbell Tweed.

Our aim is to secure balanced breeding goals for the Irish sheep industry, he stressed.

The good news is that the facts expanding network of data sources and real time information available to us is making this possible.

For example, genetic evaluations can be updated on a weekly basis. Making this possible is the fact that Sheep Ireland is a centralised data source for the entire Irish sheep industry.

McDermott particularly highlighted the role that genomics is now playing within Irelands sheep breeding sectors.

He further explained:Being able to genotype sheep brings with it many benefits. At a very fundamental level, it allows us to verify the parentage of pedigree breeding stock.

This is significant, given that up to 8% of pedigree ewes and lambs born in Ireland have been attributed the wrong ancestry, up to this point.

However, genomics opens up a host of new opportunities, when it comes to delivering improved performance at farm level.

McDermott continued:But none of this would be possible without the increasing buy-in of both pedigree and commercial sheep farmers throughout Ireland.

A total of 8 pedigree sheep societies are now using the Sheep Ireland IT system to administer their flockbooks: Belclare, Beltex, Charollais, Galway, Irish Suffolk Sheep Society, Rouge de lOuest, Texel and Vendeen.

The Sheep Ireland representative also confirmed the benefits that will be accrued by farmers using the organisations new phone app.

Essentially, it allows flockowners associated withSheep Irelandto record information about their animals, such as lambing, and growth rates on an almost real-time basis.

Kevin McDermott again: The new app allows farmers to record and submit information reliably and accurately while they are actually out in the field or in sheds.

Gone are the days when recordings are initially written down on paper and then uploaded into the Sheep Ireland once the farmer gets back to his or her office computer. As a result, the margin for error is greatly reduced.

The impact of the continuing progress made by Sheep Ireland over recent years has been significant.

The organisation was designated the responsibility of increasing the rate of genetic gain within the Irish sheep sector by identifying and promoting the use of rams with more profitable and sustainable genetics.

This has been achieved by gathering performance data from the top rams in the country and accessing their strengths and weaknesses using a genetic evaluation which is updated weekly to include any new data.

The results of these genetic evaluations are then displayed in sales catalogues and online in a simple one to five star rating system, allowing sheep farmers to make a more informed breeding decision when selecting their next stock ram.

Looking to the future, Sheep Ireland sees its role as being part of the response from Irish agriculture to the challenge of global warming.

Specifically, the organisation is currently seeking to develop an Estimated Breeding Value (EBV) for sheep, linked to their methane emissions.

Kevin McDermott again: Again, genomics can play a role in this context.

He concluded: All of the work carried out by Sheep Ireland is independently validated. This approach gives sheep producers a very high level of confidence in the performance-related data that we make available.

Dairy is the largest sector within local agriculture at the present time.

There is a growing recognition of the role that improved genetics will play in delivering future sustainability for the milk sector in Northern Ireland.

Technologies including the use of sexed semen and embryo transfer are already making a significant difference in this regard.

Ai Services Breeding Services Manager Ivan Minford takes up the story: Committing to AI has always represented a very small investment relative to the overall costs incurred within any dairy farming business. Feed, fertiliser and energy prices continue to increase at an exponential rate.

Whats more, the development of effective breeding policies has always been the cornerstone of improved herd performance that will continue to deliver for many generations.

In money terms, the size of the initial investment required to make all of this happen is inconsequential, relative to the scale of the benefits accrued.

He continued; And this remains the case. Ai Services has developed a strong working relationship with the worlds premier breeding companies to secure elite dairy genetics at prices that represent unbeatable value for money for local milk producers.

According to the Ai Services representative, an investment in improved genetics will deliver at two fundamental levels for dairy farmers: improved efficiency and improved profitably.

He further explained: Genetics impacts on every impact of cow performance: improved milk production, enhanced milk quality, extended longevity within a milking group and improved health traits to name but a few.

Significantly, all of these factors combine to deliver a smaller carbon footprint and improved sustainability for all dairy farming operations.

Cow size has also been identified as a key factor in determining the carbon footprint of all milk production business.

There is scope to reduce cow size while still maintaining overall animal performance, Minford concluded.

So how does all this fit into the future development of agriculture in Northern Ireland.

Farm Minister Edwin Poots has set out his vision for the future of farm support in Northern Ireland.

Speaking at the Irish National Ploughing Championships in Co Laois, he confirmed that the post-Brexit farm support measures will focus on a number of key themes: recognising the role of active farmers in adopting sustainable production practices, creating the conditions that will provide encouragement for young people coming into the industry and driving up efficiency levels across the industry.

Where beef is concerned, the minister referred to a revolution taking place within the sector, similar to that which has already been effected within the pig and poultry sectors.

He added:The use of improved genetics and the introduction of management systems that drive performance and reduce environmental impacts, particularly greenhouse gas emissions, are priorities for the beef industry.

Edwin Poots concluded:All future support measures will be underpinned by a measurable improvement in farm economic and environmental performance.

So there you have it: improving genetics will play a critically important role as farming in Northern Ireland looks to the future.

And no doubt, this is something that we can all look forward to.

But developing new genotypes and bloodlines is one thing: managing them effectively is another days work entirely!

Read the rest here:
The real power ofimproved genetics - Farming Life

Posted in Genetics | Comments Off on The real power ofimproved genetics – Farming Life

CIA Just Invested In Woolly Mammoth Resurrection Tech – The Intercept

Posted: October 4, 2022 at 2:00 am

As a rapidly advancing climate emergency turns the planet ever hotter, the Dallas-based biotechnology company Colossal Biosciences has a vision: To see the Woolly Mammoth thunder upon the tundra once again. Founders George Church and Ben Lamm have already racked up an impressive list of high-profile funders and investors, including Peter Thiel, Tony Robbins, Paris Hilton, Winklevoss Capital and, according to the public portfolio its venture capital arm released this month, the CIA.

Colossal says it hopes to use advanced genetic sequencing to resurrect two extinct mammals not just the giant, ice age mammoth, but also a mid-sized marsupial known as the thylacine, or Tasmanian tiger, that died out less than a century ago. On its website, the company vows: Combining the science of genetics with the business of discovery, we endeavor to jumpstart natures ancestral heartbeat.

In-Q-Tel, its new investor, is registered as a nonprofit venture capital firm funded by the CIA. On its surface, the group funds technology startups with the potential to safeguard national security. In addition to its long-standing pursuit of intelligence and weapons technologies, the CIA outfit has lately displayed an increased interest in biotechnology and particularly DNA sequencing.

Why the interest in a company like Colossal, which was founded with a mission to de-extinct the wooly mammoth and other species? reads an In-Q-Tel blog post published on September 22. Strategically, its less about the mammoths and more about the capability.

Biotechnology and the broader bioeconomy are critical for humanity to further develop. It is important for all facets of our government to develop them and have an understanding of what is possible, Colossal co-founder Ben Lammwrote in an email to The Intercept. (A spokesperson for Lamm stressed that while Thiel provided Church with$100,000 in funding to launchthe woolly mammoth project that became Colossal, he is not a stakeholderlike Robbins, Hilton, Winklevoss Capital, and In-Q-Tel.)

Colossal uses CRISPR gene editing, a method of genetic engineering based on a naturally occurring type of DNA sequence. CRISPR sequences present on their own in some bacterial cells and act as an immune defense system, allowing the cellto detect and excise viral material thattries to invade. The eponymous gene editing technique was developed to function the same way, allowing users to snip unwanted genes and program a more ideal version of the genetic code.

CRISPR is the use of genetic scissors, Robert Klitzman, a bioethicist at Columbia University and a prominent voice of caution on genetic engineering, told The Intercept. Youre going into DNA, which is a 3-billion-molecule-long chain, and clipping some of it out and replacing it. You can clip out bad mutations and put in good genes, but these editing scissors can also take out too much.

The embrace of this technology, according to In-Q-Tels blog post, will help allow U.S. government agencies to read, write, and edit genetic material, and, importantly, tosteerglobal biological phenomena that impact nation-to-nation competition whileenabling the United States to help set the ethical, as well as the technological, standards for its use.

In-Q-Tel did not respond to The Intercepts requests for comment.

In recent years, the venture firms portfolio has expanded to include Ginkgo Bioworks, a bioengineering startup focused on manufacturing bacteria for biofuel and other industrial uses; Claremont BioSolutions, a firm that produces DNA sequencing hardware; Biomatrica and T2 Biosystems, two manufacturers for DNA testing components; and Metabiota, an infectious disease mapping and risk analysis database powered by artificial intelligence. As The Intercept reported in 2016, In-Q-Tel also invested in Clearista, a skincare brand that removes a thin outer epidermal layer to reveal a fresher face beneath it and allow DNA collection from the skin cells scraped off.

President Joe Bidens administration signaled its prioritization of related advances earlier this month, when Biden signed an executive order on biotechnology and biomanufacturing. The order includes directives to spur public-private collaboration, bolster biological risk management, expand bioenergy-based products, and engage the international community to enhance biotechnology R&D cooperation in a way that is consistent with United States principles and values.

The governments penchant for controversial biotechnology long predates the Biden administration. In 2001, a New York Times investigation found that American defense agencies under Presidents George W. Bush and Bill Clinton had continued to experiment with biological weapons, despite a 1972 international treaty prohibiting them. In 2011, The Guardian revealed that the CIA under President Barack Obama organized a fake Hepatitis B vaccine drive in Pakistan that sought to locate family members of Osama bin Laden through nonconsensual DNA collection, leading the agency to eventually promise a cessation of falseimmunization campaigns.

CIA Labs, a 2020 initiative overseen by Donald Trumps CIA director, Gina Haspel infamous for running a torture laboratory in Thailand follows a model similar to In-Q-Tels. The program created a research network to incubate top talent and technology for use across U.S. defense agencies, while simultaneously allowing participating CIA officers to personally profit off their research and patents.

In-Q-Tel board members are allowed to sit on the boards of companies in which the firm invests, raising ethics concerns over howthe non-profit selects companies to back with government dollars. A 2016 Wall Street Journal investigation found that almost half of In-Q-Tel board members were connected to the companies where it had invested.

The size of In-Q-Tels stake in Colossal wont be known until the nonprofit releases its financial statements next year, but the investment may provide a boon on reputation alone: In-Q-Tel has claimed that every dollar it invests in a business attracts 15 more from other investors.

Colossals co-founders, Lamm and Church, represent the ventures business and science minds, respectively. Lamm, a self-proclaimed serial technology entrepreneur, founded his first company as a senior in college, then pivoted to mobile apps and artificial intelligence before helping to start Colossal.

Church a Harvard geneticist, genome-based dating app visionary, and former Jeffrey Epstein funding recipient has proposed the revival of extinct species before. Speaking to Der Spiegel in 2013, Church suggested the resurrection of the Neanderthal an idea met with controversy because it would require technology capable of human cloning.

We can clone all kinds of mammals, so its very likely that we could clone a human, Church said. Why shouldnt we be able to do so? When the interviewer reminded him of a ban on human cloning, Church said, And laws can change, by the way.

Even when the methods used for de-extinction are legal, many scientists are skeptical of its promise. In a 2017 paper for Nature Ecology & Evolution, a group of biologists from Canada, Australia, and New Zealand found that [s]pending limited resources on de-extinction could lead to net biodiversity loss.

De-extinction is a fairytale science, Jeremy Austin, a University of Adelaide professor and director of the Australian Center for Ancient DNA,toldthe Sydney Morning Herald over the summer, when Colossal pledged to sink $10 million into the University of Melbourne for its Tasmanian tiger project. Its pretty clear to people like me that thylacine or mammoth de-extinction is more about media attention for the scientists and less about doing serious science.

Critics who say de-extinction of genes to create proxy species is impossible are critics who are simply not fully informed and do not know the science. We have been clear from day one that on the path to de-extinction we will be developing technologies which we hope to be beneficial to both human healthcare as well as conservation, Lamm wrote to The Intercept. We will conitnue [sic] to share these technologies we develop with the world.

It remains to be seen if Colossal, with In-Q-Tels backing, can make good on its promises. And its unclear what, exactly, the intelligence world might gain from the use of CRISPR. But perhaps the CIA shares the companys altruistic, if vague, motives: To advance the economies of biology and healing through genetics. To make humanity more human. And to reawaken the lost wilds of Earth. So we, and our planet, can breathe easier.

Update: September 28, 2022, 1:00 p.m. ETThis story has been updated with a statement from Colossal co-founder Ben Lamm.

Here is the original post:
CIA Just Invested In Woolly Mammoth Resurrection Tech - The Intercept

Posted in Genetics | Comments Off on CIA Just Invested In Woolly Mammoth Resurrection Tech – The Intercept

Fighting the Monkeypox Virus: Genetics as a Predictor of Vaccinia Vaccine Effectiveness – Medical News Bulletin

Posted: October 4, 2022 at 1:59 am

Monkeypox is a painful and debilitating viral infection. Cases have been rising rapidly since April, causing the World Health Organization to declare the monkeypox outbreak a global health emergency as of July 20221. Thankfully, science is on our side and vaccinia-based vaccines may be the key to stopping another pandemic.

Vaccinia-based vaccines contain inactivated or non-pathological viruses. These types of vaccines are being explored for use against monkeypox as this type of vaccine is behind the eradication of the smallpox outbreak that wiped out millions worldwide2. Recent evidence demonstrates that these vaccines have been effective against the monkeypox virus due to a concept known as cross-reactivity.

Cross-reactivity simply means that there are similarities within each virus which may mean similar targets to develop immunity2. However, the virus responsible for smallpox is genetically different from the virus responsible for monkeypox. Due to this genetic variation, it is unknown whether the vaccinia-based vaccines would be effective2.

To gain further understanding, a group of researchers accessed public databases to compare the genetic code of the vaccinia virus pre-1980s (smallpox) and compared these to the 2022 monkeypox viruses2. The exploration focused on the segments of the viruses that are targeted by the immune system, known as epitopes. Comparing epitopes between the viruses could show how effective the vaccinia-based vaccine may be against the 2022 monkeypox virus2.

The researchers then sought to determine the degree of genetic similarity among the epitopes that are recognized by our T cells. T cells are paramount in fighting pathogens and are responsible for inducing a range of immune responses against different infectious agents1,3. These researchers found similarities among the epitopes recognized by our T cells which means there is a positive association between the vaccinia-based vaccine and the activation and function of our T cells2.

The 2022 monkeypox virus contains mostly similar epitopes to that of the vaccinia virus. This implies that the vaccinia-based vaccine may be the defense needed against this monkeypox virus and its strains2,3.

Despite these encouraging results, additional studies are warranted to discover the specificity of immune responses based on genetic differences, but similarities of epitopes observed between the 2022 monkeypox virus and the vaccinia virus3.

Here is the original post:
Fighting the Monkeypox Virus: Genetics as a Predictor of Vaccinia Vaccine Effectiveness - Medical News Bulletin

Posted in Genetics | Comments Off on Fighting the Monkeypox Virus: Genetics as a Predictor of Vaccinia Vaccine Effectiveness – Medical News Bulletin

Viewpoint: Once a biotechnology innovator, Mexico puts its farm economy in a vise, jeopardizes grain trade with the US with GMO and herbicide bans -…

Posted: October 4, 2022 at 1:58 am

In power since sweeping to victory in 2018, Mexican center-left president Andrs Manuel Lpez Obrador (AMLO) has relentlessly targeted conventional farming techniques, especially the growing and import of GMO food and animal feed. This policy reversal enraged most farmers but emboldening activist and indigenous groups that supported AMLO during the campaign.

His target: Crops modified to reduce the use of more toxic herbicides and dramatically reduce the spraying of insecticides has helped spur increased yields in many other countries.

AMLOs sharp policy reversal cites cultural concerns. He and his supporters among the organic and regenerative agriculture lobbies claim that GM crops are dangerous incursions into indigenous agriculture and its broader culture. His new policies, he claimed, would:

contribute to food security and sovereignty and protect native corn, cornfields, bio-cultural wealth, farming communities, gastronomic heritage and the health of Mexicans.

Whether AMLO succeeds with this GMO rejectionist policy remains a huge question mark. He launched this initiative in a 2020 New Years Eve decree. Mexico previously had halted all official biotechnology food or feed product approvals in 2018 but this new proposed policy went much further. He issued two presidential edicts phasing in bans on the herbicide glyphosate and genetically modified corn to full take effect by 2024. [GM corn and select other crops are modified to be resistant to the weedkiller, making pest control far easier and less expensive.]

Obrador also soon announced a three-year phaseout of the import of GM yellow corn for human consumption. Mexico, one of the largest buyers of US corn, has evolved a close partnership with Canada and the US. The grain trade between the US and Mexico has such importance that there are specific considerations in the inter-country agreement to protect farmers and their interests.

Its not clear whether the phased-in ban would also extend to the import of corn for cattle feed. Under NAFTA and its successor the three-headed trade agreement between Canada, the US and Mexico known as CUSMA, USMCA and T-MEC the United States has seen a 400% increase in corn exports to Mexico, the vast majority of it genetically modified yellow dent corn (also known as grain corn, a type of field corn with a high soft starch content).

Some Mexican officials say imports of US-grown GMO yellow corn for animal feed will continue but American farmers are skeptical noting there is no official Mexican document assuring them that these imports wont be banned as well.

Banning the import of US-grown GM corn would significantly affect US farmers and roil the food market. Closing the Mexican market to US corn could send corn prices in the US down sharply, which would be particularly painful for corn-belt states.

US Agriculture Secretary Tom Vilsack says he has discussed this issue with Obrador, stressing that halting corn shipments would hurt Mexican consumers, particularly the poor.

I informed him about the importance of understanding the role of biotechnology, the role of production and the connection with his livestock industry, Vilsack said, adding that an inconsistent message from Mexico on biotechnology could chill innovation in the sector.

But the political and activist opposition to GM and gene-edited crop varieties is fierce, led by the extremist edge of the environmental movement, mostly US-based lobby groups. For example, Pesticide Action Network, one of many advocacy groups that reject conventional agriculture and the use of genetically modified seeds, has praised the ban as a huge win for small farmers and Native communities.

PANs Mexican partner, Red de Accin sobre Plaguicidas y Alternativas en Mxico (RAPAM), hailed the decision as a cultural, enviornmental and economic victory:

[I]n order to achieve self-sufficiency and food sovereignty, our country must focus on establishing a sustainable and culturally appropriate agricultural production, through the use of practices and agroecological inputs that are safe for human health, the countrys biocultural diversity and the environment, as well as congruent with the agricultural traditions of Mexico.

Twenty months after the president announced his plan, global farming and food production are in disarray as the result of war disruptions and escalating climate events. Consequently, many Mexican farmers are having second thoughts, beset with uncertainty as agriculture officials and trade groups assess the likely negative impacts of GM crop bans, including a disruption in the Mexican food chain.

A recent report released by World Grain showed that Mexico imports approximately 17M tons/year of GM corn with the US as top supplier. A ban could increase Mexicos food insecurity and add $4.4bn to its corn imports costs.

The impact on the poor could be catastrophic if the world food crisis continues or worse, escalates. Mexico is already not a food self-sufficient nation. As Ive previously written:

Mexico is the sixth largest producer of maize in the world, but it is also a major consumer of this crop. Even though domestic production traditionally met the entire demand for white maize, the country currently has to import more than 5 million tons of white maize and 8.15 million tons of yellow maize, representing a 45 percent deficit.

If prices rise as they inevitably would under these new policies, a high percentage of the Mexican population would be unable to afford nutritious food. As the MAIZALL delegation (which includes members from the Brazilian Association of Corn Producers, Argentine Corn and Sorghum Association, the National Corn Growers Association and US Grains Council) recently noted:

It is unlikely that enough non-GM corn would be available in international markets by 2024 to meet Mexicos need, leading to food insecurity and increased prices for many of the countrys staple foods.

The AMLO Administration is selling this policy turn as the best way to protect Mexican biodiversity and culture. As political speech, it works. He and his supporters firmly believe that an increase in organic farming, as well as the adoption of ancient farming techniques such as milpa (a system in which different species coexist, sharing resources like water, light, soil and even ecological interactions, such as the nitrogen fixation provided by beans), are enough to achieve self-sufficiency in this fast-growing nation, now with 121 million people.

But farm experts and agricultural economists say there is no way to satisfy the national demand for corn by relying just on national production.

This decree is completely divorced from reality, said Jos Cacho, president of Mexicos corn industry chamber CANAMI, the 25-company group that includes top corn millers like Gruma, cereal maker Kellogg and commodity trader Cargill.

There is early evidence that the ban of glyphosate, which is being phased in, has already cut yields, with no tangible benefits to the environment or Mexican farmers. The bans have also sparked the formation of a huge black market for illegal herbicides.

Considering the key role GM corn exports have traditionally played in the state economy, a huge drop-off in maize production courts an economic disaster. A self-imposed economic contraction linked to restrictions on crop biotechnologies could position the country for a Sir Lanka-like collapse, as GM corn is deeply attached to the overall Mexican economy. The ban would disrupt well-established supply chains, from livestock to a dizzying array of condiments and sauces that use starches derived from the corn, according to Jose Cacho president of Mexicos corn industry chamber of commerce.

There is no government strategy to prepare for the unintended consequences of this sharp policy reversal. Mexico has not invested in research and development to provide alternatives for effective and inexpensive glyphosate, which almost all mainstream scientists and most farmers agree is the safest, most effective, and least costly herbicide on the market.

Obradors decree has also exacerbated internal ideological tensions, and it comes at a time when food security has emerged as one of the worlds most pressing issues. While his politics may play well in a country struggling economically, it will not help Mexico avoid a sizable food crisis largely of its own making.

Worse, this crisis comes at a time when there are emerging signs that there is not enough farmland in Mexico to satisfy domestic demand especially because of the lower yields generated by organic techniques. The yield lag runs as high as 9.5 bushels per acre for corn, the difference between losing money and surviving. A recent Purdue University study found conventional GM corn yields 32% more corn per acre.

This a case in which no one appears to benefit from what seems like a manufactured crisis. As recently reported in El Economista, US farmers have started to lobby in Washington, urging the government to protect their vulnerable farms. Washington could raise a dispute under the trade agreement clauses that address cooperation between members over regulation of individual government imports. Its not at all clear that the standing agreements will be enforced, and or if Mexico will be allowed to renege on its agreements.

Its precisely at this moment that GM corn varieties, home grown and imported, could help stabilize the economy. A state-of-the-art 2018 meta-analysis of two decades of field data on maize found planting GM variety seeds led to a yield increase of as much as 25%, while dramatically lowering the presence of health-endangering mycotoxins and other crop pests.

Despite the efforts of farmers associations and seed companies, and legal challenges, the government posture is unlikely to change anytime soon. There is fleeting hope that an alliance between chagrined scientists, disgruntled farmers and worried consumers could put pressure on Obrador to reconsider.

As the politicization of crop biotechnology has unfolded in Mexico City, the countrys crop science community has redoubled its research efforts in hopes the country will strike a better balance between innovation and cultural heritage. Key is embracing next generation GMOS and gene editing crops by relaxing strangulating regulations.

National research centers such as the CINVESTAV are developing highly productive strains of corn resistant to droughts and low temperatures. This novel variety was tested in the lab and proved to be fully functional in the field. But due to current restrictions on GM corn, this variety, like all other Mexican-developed GM crops, will remain in the laboratory and banned for use by Mexican farmers.

Luis Ventura is a biologist with expertise in biotechnology, biosafety and science communication, born and raised in a small town near Mexico City. He is a Plant Genetic Resources International Platform Fellow at the Swedish University of Agricultural Sciences. Follow him on Twitter@luisventura

Continue reading here:
Viewpoint: Once a biotechnology innovator, Mexico puts its farm economy in a vise, jeopardizes grain trade with the US with GMO and herbicide bans -...

Posted in Biotechnology | Comments Off on Viewpoint: Once a biotechnology innovator, Mexico puts its farm economy in a vise, jeopardizes grain trade with the US with GMO and herbicide bans -…

Global White Biotechnology Market Report 2022: Cost and Energy Consumption Advantage Compared to Other Technologies Drives Growth – Yahoo Finance

Posted: October 4, 2022 at 1:58 am

DUBLIN, Sept. 29, 2022 /PRNewswire/ -- The "Global White Biotechnology Market (2022-2027) by Product, Application, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global White Biotechnology Market is estimated to be worth USD 208 million in 2022, and is expected to reach USD 241.36 million by 2027, growing at a CAGR of 3.02%.

Market Segmentation

The Global White Biotechnology Market is segmented based on Product, Application, and Geography.

By Product, the market is classified into Biofuels, Biomaterials, Biochemicals, and Industrial Enzymes.

By Application, the market is classified into Cardiovascular, Neurovascular, and Urology.

By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Countries Studied

America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The Competitive Quadrant

The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global White Biotechnology Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The Global White Biotechnology Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, suitable strategies have been devised for market growth.

Story continues

Why Buy This Report?

The report offers a comprehensive evaluation of the Global White Biotechnology Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel within the industry.

The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.

The report also includes the regulatory scenario within the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules & regulations imposed on this sector across various geographies.

The report also contains competitive analysis using 'Positioning Quadrants'; a proprietary competitive positioning tool.

Market Dynamics

Drivers

Restraints

Opportunities

Increasing Investment in Biofuels

Biosynthesis of Nanomaterials by Microorganisms

Ban on the Use of Conventional Plastic

Advancement in White Biotechnology Through Fungi

Challenges

Avaliblity of the Alternatives

Shifting Consumer Preferences

Life Span and Limitation of Products

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Dynamics

5 Market Analysis

6 Global White Biotechnology Market, by Product

7 Global White Biotechnology Market, by Application

8 Americas' White Biotechnology Market

9 Europe's White Biotechnology Market

10 Middle East and Africa's White Biotechnology Market

11 APAC's White Biotechnology Market

12 Competitive Landscape

13 Company Profiles

14 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/xsn84u

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/global-white-biotechnology-market-report-2022-cost-and-energy-consumption-advantage-compared-to-other-technologies-drives-growth-301636893.html

SOURCE Research and Markets

The rest is here:
Global White Biotechnology Market Report 2022: Cost and Energy Consumption Advantage Compared to Other Technologies Drives Growth - Yahoo Finance

Posted in Biotechnology | Comments Off on Global White Biotechnology Market Report 2022: Cost and Energy Consumption Advantage Compared to Other Technologies Drives Growth – Yahoo Finance

Putnam Launches 2 Active ETFs Targeting BDCs and Biotechnology – ETF Trends

Posted: October 4, 2022 at 1:58 am

Putnam Investments announced that on Friday, September 30, it will launch two new transparent, actively managed, equity exchange traded funds: the Putnam BDC Income ETF (NYSE Arca: PBDC), concentrating on business development companies (BDCs), and the Putnam BioRevolutionETF(NYSE Arca: SYNB), centered on companies operating at the intersection of technology and biology in the biology revolution.

PBDC will represent the first actively managed BDC ETF in the marketplace, investing in a host of BDC opportunities with an eye toward generating income for investors.

Putnam is excited to bring these two dynamic new strategies to market as we seek to address the long-term investment needs of advisors and their clients, said Robert L. Reynolds, president and CEO of Putnam Investments, in a news release. Our firm is focused on providing unique and differentiated offerings delivered through a variety of vehicles that tap Putnams deep investing expertise and exceptional research capabilities.

PBDC invests in exchange traded BDCs based in the U.S. and registered with the SEC. BDCs generally invest in, lend capital to, or provide services to privately held U.S. companies or thinly traded U.S. public companies. Putnam has managed a similar non-public BDC-focused strategy for nearly five years. The fund is managed by Michael Petro.

SYNB, meanwhile, invests in companies that seek to capitalize on the convergence of technological developments in the life sciences sector, including technology-enabling companies, synthetic biology companies, and companies that operate in industries that are likely to benefit from the biology revolution. The fund is managed by William Rives.

We have identified BDCs and advances in the biology sector as providing distinctive opportunities for investors in rapidly evolving sectors of the economy, added Carlo Forcione, head of product and strategy at Putnam Investments. Our new ETFs represent innovative, early-to-market offerings that will align well with the portfolio construction needs of our clients and the broader marketplace.

The new ETFs will join Putnams existing suite of four active ETFs that the firm launched in May 2021: the Putnam Focused Large Cap Growth ETF (NYSE Arca: PGRO), the Putnam Focused Large Cap Value ETF (NYSE Arca: PVAL), the Putnam Sustainable Future ETF (NYSE Arca: PFUT), and the Putnam Sustainable Leaders ETF (NYSE Arca: PLDR).

For more news, information, and strategy, visitVettaFi.

See the original post here:
Putnam Launches 2 Active ETFs Targeting BDCs and Biotechnology - ETF Trends

Posted in Biotechnology | Comments Off on Putnam Launches 2 Active ETFs Targeting BDCs and Biotechnology – ETF Trends

Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia – Yahoo Finance

Posted: October 4, 2022 at 1:58 am

Funding of $11.1 million for two UBC projects that will improve pathogen response and boost the impact of B.C. biotechnology on the global stage

VANCOUVER, BC, Oct. 3, 2022 /CNW/ - Pacific Economic Development Canada

Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia (CNW Group/Pacific Economic Development Canada)

British Columbians continue to feel the effects of the COVID-19 pandemic, whether at home, at work, or in their community. Throughout the pandemic, science has provided the greatest defense, particularly through mRNA vaccines. These vaccines trigger the body's immune response to help protect against infection and severe illness.

Today, the Honourable Harjit S. Sajjan, Minister for International Development and Minister responsible for the Pacific Economic Development Agency of Canada (PacifiCan), announced over $11.1 million in funding through PacifiCan for the University of British Columbia (UBC) to undertake two new projects to enhance the delivery and efficacy of mRNA vaccines.

The first of these two complementary projects is receiving $3.5 million in PacifiCan support. It aims to optimize how mRNA vaccines are administered on a cellular level, improving uptake into the body. This will reduce potential side-effects of mRNA vaccines, improve their efficacy and allow for a smaller vaccine dosage. Research conducted through this project will help to streamline the production of existing mRNA vaccines and inform the development of future medicines across the globe.

The second project, with $7.6 million in PacifiCan support, aims to identify and address new COVID-19 variants before they can spread. Through studying existing variants at the molecular level, researchers will use Artificial Intelligence (AI) to predict and develop mRNA vaccine treatments for potential future pathogens. This project will enable a nimble, home-grown response to emerging COVID-19 variants, helping to protect Canadians, and further solidify B.C. as a leader in the biotechnology sector.

Investing in the health and safety of all Canadians is a key priority for the Government of Canada. In British Columbia, PacifiCan is committed to advancing the research and commercialization of life-saving biotechnology, supporting the regional economy, and building pandemic resilience across the globe.

Story continues

Quotes

"PacifiCan is committed to supporting British Columbia's life sciences sector andthese projects at the University of British Columbia reflect that commitment.Establishing a home-grown pipeline for mRNA vaccine researchwillnot only save lives, but create jobs for British Columbians and position Canada as a global leader in biotechnology innovation."

- The Honourable Harjit S. Sajjan, Minister of International Development and Minister responsible for the Pacific Economic Development Agency of Canada

"With cutting-edge research led by some of the brightest minds globally, UBC continues to excel in biotechnology and life sciences research and innovation. With the generous support of the Government of Canada through PacifiCan announced today, our researchers will be able to help development treatments for new COVID-19 variants and improve the efficacy of mRNA vaccines and other therapeutics for a wide range of diseases."

- Santa J. Ono, President and Vice-Chancellor, University of British Columbia

"UBC has long been a major driver of the B.C. biotech sector, but those connections and their outputs really gained international attention during the pandemic. AbCellera, Acuitas, and Precision Nanosystems, among many others, are now major players in the treatment and prevention of diseases. This funding builds off many years of collaboration between UBC and local biotech companies and will enable us to continue developing and refining vaccines, drugs, and biologics."

- Dr. Leonard Foster, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia

Quick facts

PacifiCan is investing $11,180,000 through its Regional Innovation Ecosystem program. This program aims to grow and nurture priority sectors across British Columbia, building an inclusive ecosystem that allows those sectors to innovate and compete globally.

Projects funded through the Regional Innovation Ecosystem program must support at least one priority sector, such as life sciences, clean technology, or agriculture. Additionally, these projects must support the hiring and training of under-represented groups, including Indigenous peoples, women, and youth.

PacifiCan is the Government of Canada's regional development agency dedicated to British Columbia. PacifiCan promotes growth and diversification in British Columbia's economy by enhancing innovation, improving business competitiveness, and promoting inclusive growth.

Associated links

Stay connected

Follow PacifiCanonTwitterandLinkedInToll-Free Number:1-888-338-9378TTY (telecommunications device for the hearing impaired):1-877-303-3388

Backgrounder: Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia

Today, the Honourable Harjit S. Sajjan, Minister of International Development and Minister responsible for the Pacific Economic Development Agency of Canada (PacifiCan), announced an investment of over $11.1 million through the Regional Innovation Ecosystem program for two projects at the University of British Columbia (UBC).

These projects will focus on advancing the delivery and efficacy of mRNA vaccine technology. The two project teams will work in tandem, meeting regularly and coordinating research to maximize the value and effectiveness of both projects.

Improve the delivery technology behind mRNA vaccines and other nanomedicines$3,500,000

The University of British Columbia will acquire key equipment and enhance lab resources to improve vaccine delivery technology. In partnership with leading B.C. biotechnology companies, UBC aims to accelerate the development of vaccine delivery techniques for commercial application on a global scale.

Through analyzing how mRNA vaccines interact with cells and create defenses against pathogens, researchers will work to optimize the administration of those vaccines. Key objectives in this research project include minimizing any potential side effects, reducing the necessary vaccine dosage, and optimizing the potency of mRNA vaccines, among others.

This work will advance the development of future mRNA vaccines and other medicines. Expected economic benefits of this project include the creation of 70 new jobs, the training of 80 new highly qualified biotechnology professionals, and revenue growth of at least $90 million for the B.C. biotechnology sector.

Grow B.C. biotech by advancing in-vitro and in-situ antiviral therapy for SARS-CoV2 variants$7,680,000

This project will see UBC acquire key equipment and enhance lab operations to advance antiviral therapy for COVID-19 variants. This will involve identifying, testing and developing responses to existing COVID-19 variants and establishing a vaccine development framework in B.C.

Working closely with B.C. biotechnology companies, UBC will study the COVID-19 Delta variant at a molecular level and use AI predictive models to create mRNA vaccine treatments for potential future variants. Through this process, UBC and its partners will develop a pipeline for rapid anti-viral drug development, enabling a local response to new and emerging COVID-19 variants for worldwide commercial application.

Overall, this will allow B.C. to provide international leadership in vaccine research and raise the visibility of B.C. biotech within the global community. Expected economic benefits of this project include creating at least 170 jobs at UBC and industry partners, training 75 highly qualified personnel and growing revenue by at least $70 million for the B.C. biotechnology sector.

SOURCE Pacific Economic Development Canada

Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2022/03/c8150.html

See the article here:
Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia - Yahoo Finance

Posted in Biotechnology | Comments Off on Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia – Yahoo Finance

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – Business Wire

Posted: October 4, 2022 at 1:58 am

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (MAIA, the Company), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that it will present the results of a study of the anticancer agent 6-thio-dG (THIO) in hepatocellular carcinoma (HCC) in vitro and in vivo models at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. The symposium is taking place Oct. 26-28, 2022, in Barcelona, Spain.

The data to be presented outline high anticancer activity of THIO in HCC cancer cells. Notably, sequential administration of THIO followed by cemiplimab (cemi) demonstrated enhanced antitumor efficacy, including complete responses, in a syngeneic immunocompetent HCC mouse model, in comparison with either single agent used alone. Moreover, the treated tumor-free mice demonstrated a complete rejection of the same tumor type cells upon re-challenge: anticancer immune memory was confirmed.

MAIA received an Orphan Drug Designation from the US FDA for the treatment of HCC with THIO earlier in 2022. HCC currently makes up around 90% of liver cancer cases; by 2025, the global incidence of liver cancer is expected to eclipse 1 million cases.1

Presentation details:

Additional meeting information is available on ENA's website.

About THIO

THIO (6-thio-dG or 6-thio-2-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC), in sequential administration with cemiplimab (Libtayo), a PD-1 inhibitor developed by Regeneron. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second or higher line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Companys lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. For more information, please visit http://www.maiabiotech.com.

1 Llovet, J.M., Kelley, R.K., Villanueva, A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6 (2021). https://doi.org/10.1038/s41572-020-00240-3

Forward Looking Statements

This press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on managements current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

See the original post here:
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Business Wire

Posted in Biotechnology | Comments Off on MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – Business Wire

China’s Syngenta pushes the edge: Can technology-driven agriculture promote a new view of sustainable farming to a world still wary of biotechnology?…

Posted: October 4, 2022 at 1:58 am

China has very small farms; there hasnt been a lot of infrastructure put in place in terms of knowledge or solid assets. Now Syngenta is enabling them with agronomists and digital infrastructure.

When it comes to Beijings technological ambitions, high profile hardware like semiconductors and electric vehicles tend to dominate global headlines. But in China, where almost 20 percent of the global population lives on 8.5 percent of the worlds arable land, finding innovative ways to reap more food from every hectare of seeds sown has long been one of the governments highest priorities.

Chinese agriculture and food demand is in inherent conflict, says Wendong Zhang, an assistant professor at Cornell Universitys Dyson School of Applied Economics and Management and a specialist in Chinas agricultural development. China wont be able to have more land. They wont be able to have better quality soil. The thing they can control is technology.

Beijings realization that technology would be key to increasing its food self-sufficiency is what made Syngenta such a valuable target for ChemChina. Syngenta, after all, is the world-leader in crop protection products and globally the number three producer of seeds, including selectively-bred hybrids and genetically modified seeds. Alongside rivals like Germanys Bayer and Americas Corteva (formerly DowDupont), the company is pushing the boundaries of seed genomics using CRISPR-Cas9, a tool that allows researchers to tweak the genetics of living organisms.

Emboldened by its ownership of Syngenta, China seems to be crossing the rubicon when it comes to high-tech agriculture. Officials are now calling cutting-edge seeds agriculture microchips, according to Chinese state media.

And safety approvals for GM seeds appear to be speeding up: in early 2022, Beijings Ministry of Agriculture and Rural Affairs (MARA) granted safety certificates to three Syngenta GM corn seeds as well as a seed from the domestic firm Hangzhou Ruifeng Bio-Tech Company and several others from Chinese universities. In June, MARA also released guidelines, for the first time, that could pave the way for companies to begin commercial planting of GM products.

And with its high-profile Shanghai listing, Syngenta might help the Chinese government out of a dilemma of its own making: convincing the general public that GMOs are safe. At the very least, the company cant be viewed as a trojan horse for U.S. bioweapons. Syngentas MAP program has even introduced QR codes on food packaging so consumers can scan their food and see a photo of the Chinese farmer who grew it.

To help itself out of its GMO bind, Beijing is also positioning its efforts in direct gene editing as a kind of technological leapfrogging these newer engineering methods do not require the introduction of foreign DNA, unlike todays genetic modification, in which bacteria from one organism is transplanted into another ( la the Bt genes added into the corn genome). As [Shane] Thomas, the analyst, notes, the industry as a whole is moving towards this more precise kind of genetic tweaking.

This is an excerpt. Read the original post here

More:
China's Syngenta pushes the edge: Can technology-driven agriculture promote a new view of sustainable farming to a world still wary of biotechnology?...

Posted in Biotechnology | Comments Off on China’s Syngenta pushes the edge: Can technology-driven agriculture promote a new view of sustainable farming to a world still wary of biotechnology?…

The Best Biotechnology Stocks to Invest in Right Now – Best Stocks

Posted: October 4, 2022 at 1:58 am

Image Source: FreeImages

The global bio-economy is growing at an incredible pace, with plenty of opportunity for investors. The biotech industry in general, and biotech stocks specifically, provide a lot of potential for long-term returns. Biotechnology is the application of biological principles to create new products and services. It has many applications, from agricultural uses to medical research and drug development. As a result, the biotechnology sector has grown strongly as other industries adopt its technologies and invest in related ventures and partnerships.Investors looking to capitalize on this growth need to understand which companies are leading the way. Fortunately, there are several great biotechnology stocks that can offer excellent returns in the coming years. Here are some of the top opportunities currently available:

Global Blood Therapeutics (GBT) is an emerging biotechnology company focused on creating therapies for rare blood diseases.GBTs lead product, Prophage, is a gene therapy designed to treat patients with beta-thalassemia, a rare inherited blood disorder.drug has been granted Orphan Drug Designation by the FDA and designation as a Breakthrough Therapy from the FDAs Oncology Drug Review Committee.GBT has also partnered with Galapagos NV, one of the top gene-therapy companies in the world. The company has a Phase 3 development program for Prophage, with a goal to complete registration in the next few years. With a potential blockbuster drug on the table, GBT has the potential to grow very quickly.

BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on bringing new therapies to patients suffering from rare diseases.BBIO has a robust product pipeline, with several therapies in Phase 1 and 2 clinical trials. The company is also in the pre-clinical development stages of several promising new therapies. BBIOs main product candidates are focused on iron-related disorders, including an iron chelating agent for patients with rare blood diseases.BBIO has partnered with some of the largest companies in the world, including The Medicines Company, Celgene, and Bayer.BBIOs therapies are currently in Phase 2 development and are expected to advance into Phase 3 in the next few years. When these drugs are approved, BBIO will be poised for growth.

SIGA Technologies (SIGA) is a biopharmaceutical company focused on creating vaccines and medicines for infectious diseases.SIGA has a robust product pipeline focused on viral diseases, including respiratory and viral hemorrhagic fever diseases. The company is currently investing in three main products.First is a universal flu vaccine designed to address issues with current flu vaccines. SIGAs universal flu vaccine is administered as a nasal spray, has no adjuvant, and is designed to provide constant immunity to the most common flu strains.Second is an Ebola vaccine designed to treat patients infected with the Ebola virus. The vaccine has been in development since 2003, when the Ebola outbreak in Africa began.Third is a therapeutic vaccine designed to treat dengue fever. The vaccine has completed Phase 1/2 trials and is expected to advance into Phase 3 trials in the next few years.

Ninety (NOVT) is a biotechnology company focused on creating therapies for the eye.NOVT is currently developing a first-in-kind therapy called a corneal scarring therapy that could replace corneal transplants in some patients.The company is expected to advance this product into Phase 3 trials in the next few years. Once the treatment is approved, it could become a huge product for NOVT.While the companys main product remains in development, it is also investing in other eye-related therapies. NOVT has a partnership with Galapagos NV to develop gene therapies for retinal diseases. The company is also developing a novel combination therapy for glaucoma.

Biotechnology is a growing industry that is expected to continue to see strong growth. The sector is also expected to see some strong mergers and acquisitions, providing another avenue for growth.Investors looking for growth in the biotechnology industry can consider investing in any of the top biotechnology stocks above. These companies are all poised for growth over the next several years, and could offer excellent returns for investors.

Image Source: FreeImages

The global economy is growing incredibly, with plenty of opportunities for investors. The biotech industry, in general, and biotech stocks, provide a lot of potential for long-term returns. Biotechnology is the application of biological principles to create new products and services. It has many applications, from agricultural uses to medical research and drug development. As a result, biotechnology has grown strongly as other industries adopt its technologies and invest in related ventures and partnerships. Investors looking to capitalize on this growth need to understand which companies are leading the way. Fortunately, several great biotechnology stocks can offer excellent returns in the coming years. Here are some of the top opportunities currently available:

Global Blood Therapeutics (GBT) is an emerging biotechnology company focused on creating therapies for rare blood diseases.GBTs lead product, Prophage, is a gene therapy designed to treat patients with beta-thalassemia, a rare inherited blood disorder. The drug has been granted Orphan Drug Designation by the FDA and designated as a Breakthrough Therapy by the FDAs Oncology Drug Review Committee.GBT has also partnered with Galapagos NV, one of the top gene-therapy companies in the world. In addition, the company has a Phase 3 development program for Prophage, to complete registration in the next few years. With a potential blockbuster drug on the table, GBT has the potential to grow very quickly.

BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on bringing new therapies to patients suffering from rare diseases.BBIO has a robust product pipeline, with several therapies in Phase 1 and 2 clinical trials. The company is also in the pre-clinical development stages of several promising new therapies. BBIOs main product candidates are focused on iron-related disorders, including an iron chelating agent for patients with rare blood diseases.BBIO has partnered with some of the largest companies in the world, including The Medicines Company, Celgene, and Bayer.BBIOs therapies are currently in Phase 2 development and are expected to advance into Phase 3 in the next few years. When these drugs are approved, BBIO will be poised for growth.

SIGA Technologies (SIGA) is a biopharmaceutical company focused on creating vaccines and medicines for infectious diseases.SIGAs robust product pipeline focused on viral diseases, including respiratory and viral hemorrhagic fever. The company is currently investing in three main products:

The vaccine has completed Phase 1/2 trials and is expected to advance into Phase 3 trials in the next few years.

Ninety (NOVT) is a biotechnology company focused on creating therapies for the eye.NOVT is currently developing a first-in-kind therapy called corneal scarring therapy that could replace corneal transplants in some patients. The company is expected to advance this product into Phase 3 trials in the next few years. Once approved, the treatment could become a huge product for NOVT. While the companys main product remains developing, it is also investing in other eye-related therapies. For example, NOVT partnered with Galapagos NV to develop gene therapies for retinal diseases. In addition, the company is also developing a novel combination therapy for glaucoma.

Biotechnology is a growing industry that is expected to continue to see strong growth. The sector is also expected to see strong mergers and acquisitions, providing another avenue for growth. Investors looking for growth in the biotechnology industry can consider investing in any of the top biotechnology stocks above. These companies are poised for growth over the next several years and could offer excellent returns for investors.

Go here to see the original:
The Best Biotechnology Stocks to Invest in Right Now - Best Stocks

Posted in Biotechnology | Comments Off on The Best Biotechnology Stocks to Invest in Right Now – Best Stocks

Page 188«..1020..187188189190..200210..»